يعرض 1 - 12 نتائج من 12 نتيجة بحث عن '"intestine perforation/si [Side Effect]"', وقت الاستعلام: 0.46s تنقيح النتائج
  1. 1
    Electronic Resource

    مصطلحات الفهرس: intestine fistula/si [Side Effect], intestine perforation/si [Side Effect], large intestine perforation/si [Side Effect], lung embolism/si [Side Effect], major clinical study, male, metastatic colorectal cancer/dt [Drug Therapy], mucosa inflammation/si [Side Effect], multicenter study, multiple cycle treatment, nausea/si [Side Effect], neutropenia/si [Side Effect], neutrophil lymphocyte ratio, open study, overall survival, paresthesia/si [Side Effect], perianal abscess/si [Side Effect], peripheral neuropathy/si [Side Effect], phase 4 clinical trial, progression free survival, proteinuria/si [Side Effect], proteomics, rectum perforation/si [Side Effect], survival rate, treatment outcome, vomiting/si [Side Effect], bevacizumab/ae [Adverse Drug Reaction], bevacizumab/ct [Clinical Trial], bevacizumab/dt [Drug Therapy], capecitabine plus oxaliplatin/ct [Clinical Trial], capecitabine plus oxaliplatin/dt [Drug Therapy], proteome/ec [Endogenous Compound], capecitabine plus oxaliplatin/ae [Adverse Drug Reaction], abdominal pain/si [Side Effect], adult, aged, alopecia/si [Side Effect], anus fistula/si [Side Effect], article, cancer combination chemotherapy, cancer prognosis, carcinoma in situ/dt [Drug Therapy], constipation/si [Side Effect], controlled study, decreased appetite/si [Side Effect], diarrhea/si [Side Effect], digestive system perforation/si [Side Effect], drug safety, epistaxis/si [Side Effect], exploratory research, fatigue/si [Side Effect], female, gastroesophageal reflux/si [Side Effect], hand foot syndrome/si [Side Effect], human, hypertension/si [Side Effect], Article

    URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/29334
    PLoS ONE
    Click here for full text options
    LibKey Link

  2. 2
    Electronic Resource

    مصطلحات الفهرس: intestine fistula/si [Side Effect], intestine perforation/si [Side Effect], large intestine perforation/si [Side Effect], lung embolism/si [Side Effect], major clinical study, male, metastatic colorectal cancer/dt [Drug Therapy], mucosa inflammation/si [Side Effect], multicenter study, multiple cycle treatment, nausea/si [Side Effect], neutropenia/si [Side Effect], neutrophil lymphocyte ratio, open study, overall survival, paresthesia/si [Side Effect], perianal abscess/si [Side Effect], peripheral neuropathy/si [Side Effect], phase 4 clinical trial, progression free survival, proteinuria/si [Side Effect], proteomics, rectum perforation/si [Side Effect], survival rate, treatment outcome, vomiting/si [Side Effect], bevacizumab/ae [Adverse Drug Reaction], bevacizumab/ct [Clinical Trial], bevacizumab/dt [Drug Therapy], capecitabine plus oxaliplatin/ct [Clinical Trial], capecitabine plus oxaliplatin/dt [Drug Therapy], proteome/ec [Endogenous Compound], capecitabine plus oxaliplatin/ae [Adverse Drug Reaction], abdominal pain/si [Side Effect], adult, aged, alopecia/si [Side Effect], anus fistula/si [Side Effect], article, cancer combination chemotherapy, cancer prognosis, carcinoma in situ/dt [Drug Therapy], constipation/si [Side Effect], controlled study, decreased appetite/si [Side Effect], diarrhea/si [Side Effect], digestive system perforation/si [Side Effect], drug safety, epistaxis/si [Side Effect], exploratory research, fatigue/si [Side Effect], female, gastroesophageal reflux/si [Side Effect], hand foot syndrome/si [Side Effect], human, hypertension/si [Side Effect], Article

  3. 3
    Electronic Resource

    مصطلحات الفهرس: endometrium cancer/di [Diagnosis], endometrium cancer/dt [Drug Therapy], endometrium cancer/et [Etiology], enzyme inhibition, fatigue/si [Side Effect], female, fever/si [Side Effect], gastroesophageal reflux/si [Side Effect], glossodynia/si [Side Effect], hand foot syndrome/si [Side Effect], headache/si [Side Effect], human, hyperkeratosis/si [Side Effect], hypertension/si [Side Effect], hypomagnesemia/si [Side Effect], hypophosphatemia/si [Side Effect], hypotension/si [Side Effect], insomnia/si [Side Effect], intestine obstruction/si [Side Effect], intestine perforation/si [Side Effect], lethargy/si [Side Effect], limb pain/si [Side Effect], major clinical study, male, maximum plasma concentration, maximum tolerated dose, melanoma/di [Diagnosis], melanoma/dt [Drug Therapy], melanoma/et [Etiology], multiple cycle treatment, muscle spasm/si [Side Effect], musculoskeletal chest pain/si [Side Effect], myalgia/si [Side Effect], nausea/si [Side Effect], neutropenia/si [Side Effect], non small cell lung cancer/di [Diagnosis], non small cell lung cancer/dt [Drug Therapy], non small cell lung cancer/et [Etiology], oncogene N ras, oropharynx pain/si [Side Effect], ovary cancer/di [Diagnosis], ovary cancer/dt [Drug Therapy], ovary cancer/et [Etiology], palmoplantar keratoderma/si [Side Effect], pericardial effusion/si [Side Effect], phase 1 clinical trial, photosensitivity/si [Side Effect], pleura effusion/si [Side Effect], positron emission tomography-computed tomography, priority journal, progression free survival, pruritus/si [Side Effect], QT prolongation/si [Side Effect], rash/si [Side Effect], sepsis/si [Side Effect], side effect/si [Side Effect], skin defect/si [Side Effect], skin hypertrophy/si [Side Effect], solid malignant neoplasm, thrombocytopenia/si [Side Effect], thrush/si [Side Effect], thyroid cancer/di [Diagnosis], thyroid cancer/dt [Drug Therapy], thyroid cancer/et [Etiology], thyroid papillary carcinoma/di [Diagnosis], thyroid papillary carcinoma/dt [Drug Therapy], thyroid papillary carcinoma/et [Etiology], treatment duration, upper abdominal pain/si [Side Effect], upper respiratory tract infection/si [Side Effect], urinary tract infection/si [Side Effect], vomiting/si [Side Effect], xerostomia/si [Side Effect], alanine aminotransferase/ec [Endogenous Compound], B Raf kinase/ec [Endogenous Compound], K ras protein/ec [Endogenous Compound], lifirafenib/ae [Adverse Drug Reaction], lifirafenib/ct [Clinical Trial], lifirafenib/cr [Drug Concentration], lifirafenib/do [Drug Dose], lifirafenib/dt [Drug Therapy], lifirafenib/to [Drug Toxicity], lifirafenib/pd [Pharmacology], dizziness/si [Side Effect], abdominal pain/si [Side Effect], adult, aged, alanine aminotransferase blood level, anemia/si [Side Effect], antineoplastic activity, arthralgia/si [Side Effect], article, backache/si [Side Effect], blood level, blood toxicity/si [Side Effect], body weight disorder/si [Side Effect], body weight loss, brain hemorrhage/si [Side Effect], cancer chemotherapy, cancer patient, cancer radiotherapy, cancer staging, cancer survival, chill/si [Side Effect], cohort analysis, colorectal cancer/di [Diagnosis], colorectal cancer/dt [Drug Therapy], colorectal cancer/et [Etiology], constipation/si [Side Effect], coughing/si [Side Effect], decreased appetite/si [Side Effect], dermatitis/si [Side Effect], diarrhea/si [Side Effect], disease exacerbation/si [Side Effect], drug blood level, drug dose increase, drug half life, drug safety, drug tolerability, dry skin/si [Side Effect], dysgeusia/si [Side Effect], dysphonia/si [Side Effect], dyspnea/si [Side Effect], Article

    URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/28975
    Journal of Clinical Oncology
    Click here for full text options
    LibKey Link

  4. 4
    Electronic Resource

    مصطلحات الفهرس: endometrium cancer/di [Diagnosis], endometrium cancer/dt [Drug Therapy], endometrium cancer/et [Etiology], enzyme inhibition, fatigue/si [Side Effect], female, fever/si [Side Effect], gastroesophageal reflux/si [Side Effect], glossodynia/si [Side Effect], hand foot syndrome/si [Side Effect], headache/si [Side Effect], human, hyperkeratosis/si [Side Effect], hypertension/si [Side Effect], hypomagnesemia/si [Side Effect], hypophosphatemia/si [Side Effect], hypotension/si [Side Effect], insomnia/si [Side Effect], intestine obstruction/si [Side Effect], intestine perforation/si [Side Effect], lethargy/si [Side Effect], limb pain/si [Side Effect], major clinical study, male, maximum plasma concentration, maximum tolerated dose, melanoma/di [Diagnosis], melanoma/dt [Drug Therapy], melanoma/et [Etiology], multiple cycle treatment, muscle spasm/si [Side Effect], musculoskeletal chest pain/si [Side Effect], myalgia/si [Side Effect], nausea/si [Side Effect], neutropenia/si [Side Effect], non small cell lung cancer/di [Diagnosis], non small cell lung cancer/dt [Drug Therapy], non small cell lung cancer/et [Etiology], oncogene N ras, oropharynx pain/si [Side Effect], ovary cancer/di [Diagnosis], ovary cancer/dt [Drug Therapy], ovary cancer/et [Etiology], palmoplantar keratoderma/si [Side Effect], pericardial effusion/si [Side Effect], phase 1 clinical trial, photosensitivity/si [Side Effect], pleura effusion/si [Side Effect], positron emission tomography-computed tomography, priority journal, progression free survival, pruritus/si [Side Effect], QT prolongation/si [Side Effect], rash/si [Side Effect], sepsis/si [Side Effect], side effect/si [Side Effect], skin defect/si [Side Effect], skin hypertrophy/si [Side Effect], solid malignant neoplasm, thrombocytopenia/si [Side Effect], thrush/si [Side Effect], thyroid cancer/di [Diagnosis], thyroid cancer/dt [Drug Therapy], thyroid cancer/et [Etiology], thyroid papillary carcinoma/di [Diagnosis], thyroid papillary carcinoma/dt [Drug Therapy], thyroid papillary carcinoma/et [Etiology], treatment duration, upper abdominal pain/si [Side Effect], upper respiratory tract infection/si [Side Effect], urinary tract infection/si [Side Effect], vomiting/si [Side Effect], xerostomia/si [Side Effect], alanine aminotransferase/ec [Endogenous Compound], B Raf kinase/ec [Endogenous Compound], K ras protein/ec [Endogenous Compound], lifirafenib/ae [Adverse Drug Reaction], lifirafenib/ct [Clinical Trial], lifirafenib/cr [Drug Concentration], lifirafenib/do [Drug Dose], lifirafenib/dt [Drug Therapy], lifirafenib/to [Drug Toxicity], lifirafenib/pd [Pharmacology], dizziness/si [Side Effect], abdominal pain/si [Side Effect], adult, aged, alanine aminotransferase blood level, anemia/si [Side Effect], antineoplastic activity, arthralgia/si [Side Effect], article, backache/si [Side Effect], blood level, blood toxicity/si [Side Effect], body weight disorder/si [Side Effect], body weight loss, brain hemorrhage/si [Side Effect], cancer chemotherapy, cancer patient, cancer radiotherapy, cancer staging, cancer survival, chill/si [Side Effect], cohort analysis, colorectal cancer/di [Diagnosis], colorectal cancer/dt [Drug Therapy], colorectal cancer/et [Etiology], constipation/si [Side Effect], coughing/si [Side Effect], decreased appetite/si [Side Effect], dermatitis/si [Side Effect], diarrhea/si [Side Effect], disease exacerbation/si [Side Effect], drug blood level, drug dose increase, drug half life, drug safety, drug tolerability, dry skin/si [Side Effect], dysgeusia/si [Side Effect], dysphonia/si [Side Effect], dyspnea/si [Side Effect], Article

    URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/28975
    Journal of Clinical Oncology
    LibKey Link

  5. 5
    Electronic Resource

    مصطلحات الفهرس: pruritus/si [Side Effect], randomized controlled trial, rash/si [Side Effect], respiratory failure/si [Side Effect], rhabdomyolysis/si [Side Effect], sepsis/si [Side Effect], Stevens Johnson syndrome/si [Side Effect], survival analysis, systemic lupus erythematosus/si [Side Effect], toxic hepatitis/si [Side Effect], treatment duration, adrenal insufficiency/si [Side Effect], aged, anemia/si [Side Effect], article, backache/si [Side Effect], cardiopulmonary insufficiency/si [Side Effect], chromosome analysis, colitis/si [Side Effect], computer assisted tomography, constipation/si [Side Effect], controlled study, coughing/si [Side Effect], decreased appetite/si [Side Effect], dermatitis/si [Side Effect], diarrhea/si [Side Effect], disease exacerbation/si [Side Effect], drug efficacy, drug eruption/si [Side Effect], drug safety, drug withdrawal, dry skin/si [Side Effect], dyspnea/si [Side Effect], erythema/si [Side Effect], erythema multiforme/si [Side Effect], fatigue/si [Side Effect], female, fever/si [Side Effect], Food and Drug Administration, health care quality, heart arrest/si [Side Effect], heart failure/si [Side Effect], human, hypersensitivity/si [Side Effect], hyperthyroidism/si [Side Effect], hypokalemia/si [Side Effect], hypothyroidism/si [Side Effect], infusion related reaction/si [Side Effect], insomnia/si [Side Effect], insulin dependent diabetes mellitus/si [Side Effect], intestine ischemia/si [Side Effect], intestine perforation/si [Side Effect], kidney failure/si [Side Effect], low drug dose, lung embolism/si [Side Effect], major clinical study, male, mortality rate, multicenter study, multiple myeloma/dt [Drug Therapy], myasthenia gravis/si [Side Effect], myocarditis/si [Side Effect], nausea/si [Side Effect], neutropenia/si [Side Effect], nuclear magnetic resonance imaging, open study, overall survival, pancreatitis/si [Side Effect], peripheral edema/si [Side Effect], phase 3 clinical trial, pneumonia/si [Side Effect], positron emission tomography, priority journal, progression free survival, quality of life assessment, upper gastrointestinal bleeding/si [Side Effect], upper respiratory tract infection/si [Side Effect], vomiting/si [Side Effect], dexamethasone/ae [Adverse Drug Reaction], dexamethasone/ct [Clinical Trial], dexamethasone/cb [Drug Combination], dexamethasone/dt [Drug Therapy], dexamethasone/po [Oral Drug Administration], dexamethasone/pv [Special Situation for Pharmacovigilance], lenalidomide/ae [Adverse Drug Reaction], lenalidomide/ct [Clinical Trial], lenalidomide/cb [Drug Combination], lenalidomide/dt [Drug Therapy], lenalidomide/po [Oral Drug Administration], lenalidomide/pv [Special Situation for Pharmacovigilance], pembrolizumab/ae [Adverse Drug Reaction], pembrolizumab/ct [Clinical Trial], pembrolizumab/cb [Drug Combination], pembrolizumab/dt [Drug Therapy], pembrolizumab/iv [Intravenous Drug Administration], pembrolizumab/pv [Special Situation for Pharmacovigilance], Article

    URL: Click here for full text options
    LibKey Link

  6. 6
    Electronic Resource

    مصطلحات الفهرس: pruritus/si [Side Effect], randomized controlled trial, rash/si [Side Effect], respiratory failure/si [Side Effect], rhabdomyolysis/si [Side Effect], sepsis/si [Side Effect], Stevens Johnson syndrome/si [Side Effect], survival analysis, systemic lupus erythematosus/si [Side Effect], toxic hepatitis/si [Side Effect], treatment duration, adrenal insufficiency/si [Side Effect], aged, anemia/si [Side Effect], article, backache/si [Side Effect], cardiopulmonary insufficiency/si [Side Effect], chromosome analysis, colitis/si [Side Effect], computer assisted tomography, constipation/si [Side Effect], controlled study, coughing/si [Side Effect], decreased appetite/si [Side Effect], dermatitis/si [Side Effect], diarrhea/si [Side Effect], disease exacerbation/si [Side Effect], drug efficacy, drug eruption/si [Side Effect], drug safety, drug withdrawal, dry skin/si [Side Effect], dyspnea/si [Side Effect], erythema/si [Side Effect], erythema multiforme/si [Side Effect], fatigue/si [Side Effect], female, fever/si [Side Effect], Food and Drug Administration, health care quality, heart arrest/si [Side Effect], heart failure/si [Side Effect], human, hypersensitivity/si [Side Effect], hyperthyroidism/si [Side Effect], hypokalemia/si [Side Effect], hypothyroidism/si [Side Effect], infusion related reaction/si [Side Effect], insomnia/si [Side Effect], insulin dependent diabetes mellitus/si [Side Effect], intestine ischemia/si [Side Effect], intestine perforation/si [Side Effect], kidney failure/si [Side Effect], low drug dose, lung embolism/si [Side Effect], major clinical study, male, mortality rate, multicenter study, multiple myeloma/dt [Drug Therapy], myasthenia gravis/si [Side Effect], myocarditis/si [Side Effect], nausea/si [Side Effect], neutropenia/si [Side Effect], nuclear magnetic resonance imaging, open study, overall survival, pancreatitis/si [Side Effect], peripheral edema/si [Side Effect], phase 3 clinical trial, pneumonia/si [Side Effect], positron emission tomography, priority journal, progression free survival, quality of life assessment, upper gastrointestinal bleeding/si [Side Effect], upper respiratory tract infection/si [Side Effect], vomiting/si [Side Effect], dexamethasone/ae [Adverse Drug Reaction], dexamethasone/ct [Clinical Trial], dexamethasone/cb [Drug Combination], dexamethasone/dt [Drug Therapy], dexamethasone/po [Oral Drug Administration], dexamethasone/pv [Special Situation for Pharmacovigilance], lenalidomide/ae [Adverse Drug Reaction], lenalidomide/ct [Clinical Trial], lenalidomide/cb [Drug Combination], lenalidomide/dt [Drug Therapy], lenalidomide/po [Oral Drug Administration], lenalidomide/pv [Special Situation for Pharmacovigilance], pembrolizumab/ae [Adverse Drug Reaction], pembrolizumab/ct [Clinical Trial], pembrolizumab/cb [Drug Combination], pembrolizumab/dt [Drug Therapy], pembrolizumab/iv [Intravenous Drug Administration], pembrolizumab/pv [Special Situation for Pharmacovigilance], Article

  7. 7
    Electronic Resource
  8. 8
    Electronic Resource
  9. 9
    Electronic Resource

    URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/30424
    Journal of Clinical Oncology
    Click here for full text options
    LibKey Link

  10. 10
    Electronic Resource

    URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/30424
    Journal of Clinical Oncology
    LibKey Link

  11. 11
    Electronic Resource

    URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/31938
    Click here for full text options
    LibKey Link

  12. 12
    Electronic Resource